We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-0.39%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.25B
AUM Growth
-$167M
(-6.9%)
Cap. Flow
-$1.74M
Cap. Flow
% of AUM
-0.08%
Top 10 Holdings %
Top 10 Hldgs %
64.56%
Holding
59
New
8
Increased
7
Reduced
14
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
+$90.7M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$53.5M |
| 3 |
OKUR
OnKure Therapeutics
OKUR
|
+$38.3M |
| 4 |
VERV
Verve Therapeutics
VERV
|
+$32.9M |
| 5 |
AbCellera Biologics
ABCL
|
+$11.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Harmony Biosciences
HRMY
|
+$57.4M |
| 2 |
Inogen
INGN
|
+$43M |
| 3 |
Cable One
CABO
|
+$38.6M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$36.6M |
| 5 |
EAR
Eargo, Inc. Common Stock
EAR
|
+$21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.05% |
| 2 | Financials | 7% |
| 3 | Technology | 6.3% |
| 4 | Consumer Discretionary | 2.54% |
| 5 | Communication Services | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AFIB
51
DELISTED
Acutus Medical Inc
AFIB
| $4.33M | 0.19% |
255,000
| – | – |
|
52
Pharvaris
PHVS
$2.44B
| $2.07M | 0.09% |
111,144
+61,144
| +122% | +$1.39M |
|
|
BNT
53
Brookfield Wealth Solutions
BNT
$12.2B
| $1.1M | 0.05% |
+31,769
| New | +$1.21M |
|
|
FSTX
54
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $23K | ﹤0.01% |
2,703
-32,116
| -92% | -$274K |
|
55
CalciMedica
CALC
$10.9M
| – | – |
-14,982
| Closed | -$1.16M |
|
56
Crinetics Pharmaceuticals
CRNX
$8.92B
| – | – |
-271,378
| Closed | -$4.15M |
|
57
Vaxcyte
PCVX
$8.64B
| – | – |
-416,937
| Closed | -$8.23M |
|
|
GRTS
58
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-278,478
| Closed | -$2.63M |
|
|
CNST
59
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-699,415
| Closed | -$16.4M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q2 2021 Portfolio in Review
As of Q2 2021, Novo Holdings A/S held 59 positions worth $2.25B, down 6.9% from $2.42B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Novo Holdings A/S's Q2 2021 filing shows 8 new, 7 increased, 14 reduced and 5 closed positions. Its largest new stake was Cyteir Therapeutics, Inc. Common Stock: 4,840,413 shares worth $104M. The largest sale was Harmony Biosciences, an estimated $57.4M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 65% a quarter earlier, followed by Financials and Technology.
- Novo Holdings A/S's largest Q2 2021 buy was Cyteir Therapeutics, Inc. Common Stock: 4,840,413 shares worth $104M.
- Novo Holdings A/S added most to Insmed in Q2 2021, an estimated $7.1M increase.
- Novo Holdings A/S's biggest Q2 2021 reduction was Harmony Biosciences, cutting an estimated $57.4M.
- Novo Holdings A/S fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $16.4M.
- Novo Holdings A/S's ten largest holdings make up 65% of its $2.25B portfolio in Q2 2021.
- Novo Holdings A/S opened 8 new positions and closed 5 in Q2 2021.
- Novo Holdings A/S's portfolio value fell 6.9% quarter-over-quarter to $2.25B.
Based on Novo Holdings A/S's 13F filing for Q2 2021, filed 16 Aug 2021.